Validating new tuberculosis computational models with public whole cell screening aerobic activity datasets

Pharmaceutical Research

Volumn 28, Issue 8, 2011, Pages 1859-1869

  Ekins, Sean ^a,b,c,d   Freundlich, Joel S ^e  

^a Collaborative Drug Discovery ^*  (United States)

^b Collaborations in Chemistry ^*  (United States)

^c UNIVERSITY OF MARYLAND   (United States)

^d RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^e TEXAS A AND M UNIVERSITY   (United States)

Author keywords

Bayesian models; Collaborative Drug Discovery; function class fingerprints; mycobacterium tuberculosis; Quantitative Structure Activity Relationship; tuberculosis; tuberculosis database

Indexed keywords

6,7 DIHYDRO 2 NITRO 6 (4 TRIFLUOROMETHOXYBENZYLOXY) 5H IMIDAZO[2,1 B][1,3]OXAZINE; ACONIAZIDE; BISMUTH NITRATE; CEFMENOXIME; CETALKONIUM CHLORIDE; CHLORHEXIDINE; DELAMANID; DEMECARIUM; DOXYCYCLINE; DOXYCYCLINE HYCLATE; HEXADIMETHRINE BROMIDE; LOMEFLOXACIN; METHYLBENZETHONIUM CHLORIDE; METHYLENE BLUE; MINOCYCLINE; OXICONAZOLE; PRIMAQUINE; PYRITHIONE; PYRVINIUM EMBONATE; SULFATHIAZOLE; TETRACYCLINE; TONZONIUM BROMIDE; TRIPLE DYE; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG;

AEROBIC BACTERIUM; ANAEROBIC BACTERIUM; ANTIBACTERIAL ACTIVITY; BAYESIAN LEARNING; COLLABORATIVE DRUG DISCOVERY TUBERCULOSIS DATABASE; CONTROLLED STUDY; DATA BASE; DRUG APPROVAL; DRUG INDUSTRY; DRUG SCREENING; DRUG STRUCTURE; FOOD AND DRUG ADMINISTRATION; HIGH THROUGHPUT SCREENING; MATHEMATICAL COMPUTING; MATHEMATICAL MODEL; MYCOBACTERIUM TUBERCULOSIS; PRIORITY JOURNAL; REVIEW; STRUCTURE ANALYSIS; VALIDATION STUDY; WHOLE CELL;

ANTITUBERCULAR AGENTS; BAYES THEOREM; COMPUTER SIMULATION; DATABASES, FACTUAL; DRUG DISCOVERY; MODELS, BIOLOGICAL; MYCOBACTERIUM TUBERCULOSIS; SMALL MOLECULE LIBRARIES; TUBERCULOSIS;

EID: 79961170425     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-011-0413-x     Document Type: Review

References (32)

1. TS Balganesh PM Alzari ST Cole 2008 Rising standards for tuberculosis drug development Trends Pharmacol Sci 29 576 81 18799223 10.1016/j.tips.2008.08. 001 1:CAS:528:DC%2BD1cXhtlaqt7nE
2. Y Zhang 2005 The magic bullets and tuberculosis drug targets Annu Rev Pharmacol Toxicol 45 529 64 15822188 10.1146/annurev.pharmtox.45.120403.100120 1:CAS:528:DC%2BD2MXisVWjtLg%3D (Pubitemid 40261816)
3. L Ballel RA Field K Duncan RJ Young 2005 New small-molecule synthetic antimycobacterials Antimicrob Agents Chemother 49 2153 63 10.1128/AAC.49.6.2153- 2163.2005 (Pubitemid 40734441)
4. G Schneider 2010 Virtual screening: an endless staircase? Nat Rev Drug Discov 9 273 6 20357802 10.1038/nrd3139 1:CAS:528:DC%2BC3cXktVGjur4%3D
5. P Prathipati NL Ma TH Keller 2008 Global Bayesian models for the prioritization of antitubercular agents J Chem Inf Model 48 2362 70 19053518 10.1021/ci800143n 1:CAS:528:DC%2BD1cXhtlygs7vI
6. Y Cho TR Ioerger JC Sacchettini 2008 Discovery of novel nitrobenzothiazole inhibitors for Mycobacterium tuberculosis ATP phosphoribosyl transferase (HisG) through virtual screening J Med Chem 51 5984 92 18778048 10.1021/jm800328v 1:CAS:528:DC%2BD1cXhtVymtb3L
7. TI Oprea AM Davis SJ Teague PD Leeson 2001 Is there a difference between leads and drugs? A historical perspective J Chem Inf Comput Sci 41 1308 15 11604031 1:CAS:528:DC%2BD3MXlt1Okt7s%3D
8. DR Jones S Ekins L Li SD Hall 2007 Computational approaches that predict metabolic intermediate complex formation with CYP3A4 (+b5) Drug Metab Dispos 35 1466 75 17537872 10.1124/dmd.106.014613 1:CAS:528:DC%2BD2sXpslKru7s%3D (Pubitemid 47296037)
9. S Ananthan ER Faaleolea RC Goldman JV Hobrath CD Kwong BE Laughon, et al. 2009 High-throughput screening for inhibitors of Mycobacterium tuberculosis H37Rv Tuberculosis (Edinburgh, Scotland) 89 334 53 10.1016/j.tube.2009.05.008 1:CAS:528:DC%2BC3cXhtlaktbs%3D
10. S Ekins T Kaneko CA Lipinksi J Bradford K Dole A Spektor, et al. 2010 Analysis and hit filtering of a very large library of compounds screened against Mycobacterium tuberculosis Mol Biosyst 6 2316 24 20835433 10.1039/c0mb00104j 1:CAS:528:DC%2BC3cXht1KqtL7L
11. S Ekins AJ Williams 2010 Meta-analysis of molecular property patterns and filtering of public datasets of antimalarial "hits" and drugs Med Chem Comm 1 325 30 10.1039/c0md00129e 1:CAS:528:DC%2BC3cXhsVeku7zM
12. S Ekins AJ Williams 2010 When pharmaceutical companies publish large datasets: an abundance of riches or fool's gold? Drug Disc Today 15 812 5 10.1016/j.drudis.2010.08.010
13. JR Huth R Mendoza ET Olejniczak RW Johnson DA Cothron Y Liu, et al. 2005 ALARM NMR: a rapid and robust experimental method to detect reactive false positives in biochemical screens J Am Chem Soc 127 217 24 15631471 10.1021/ja0455547 1:CAS:528:DC%2BD2cXhtVCrurrF (Pubitemid 40094385)
14. JR Huth D Song RR Mendoza CL Black-Schaefer JC Mack SA Dorwin, et al. 2007 Toxicological evaluation of thiol-reactive compounds identified using a la assay to detect reactive molecules by nuclear magnetic resonance Chem Res Toxicol 20 1752 9 18001056 10.1021/tx700319t 1:CAS:528:DC%2BD2sXhtlSkurjP
15. JT Metz JR Huth PJ Hajduk 2007 Enhancement of chemical rules for predicting compound reactivity towards protein thiol groups J Comput Aided Mol Des 21 139 44 17340041 10.1007/s10822-007-9109-z 1:CAS:528:DC%2BD2sXis1Knt78%3D (Pubitemid 46416673)
16. AJ Williams V Tkachenko C Lipinski A Tropsha S Ekins 2009 Free online resources enabling crowdsourced drug discovery Drug Discov World 10 33 8 1:CAS:528:DC%2BD1MXjvVygtrc%3D
17. KE Lougheed DL Taylor SA Osborne JS Bryans RS Buxton 2009 New anti-tuberculosis agents amongst known drugs Tuberculosis (Edinburgh, Scotland) 89 364 70 10.1016/j.tube.2009.07.002 1:CAS:528:DC%2BC3cXhtlakur4%3D
18. Lamichhane G, Freundlich JS, Ekins S, Wickramaratne N, Bishai WR. Essential metabolites of M. tuberculosis and their Mimics. Mbio. 2011;2:e00301-10.
19. Ekins S, Freundlich JS, Choi I, Sarker M, Talcott C. Computational databases, pathway and cheminformatics tools for tuberculosis drug discovery. Trends Microbiol. 2011;19:65-74.
20. S Ekins J Bradford K Dole A Spektor K Gregory D Blondeau, et al. 2010 A collaborative database and computational models for tuberculosis drug discovery Mol Biol Syst 6 840 51 1:CAS:528:DC%2BC3cXlvVSrtrg%3D
21. http://www.collaborativedrug.com/register. http://www.collaborativedrug. com/register.
22. CA Lipinski F Lombardo BW Dominy PJ Feeney 1997 Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings Adv Drug Deliv Rev 23 3 25 10.1016/S0169-409X(96)00423-1 1:CAS:528:DyaK2sXktlKlsQ%3D%3D (Pubitemid 27046991)
23. M Zientek C Stoner R Ayscue J Klug-McLeod Y Jiang M West, et al. 2010 Integrated in silico-in vitro strategy for addressing cytochrome P450 3A4 time-dependent inhibition Chem Res Toxicol 23 664 76 20151638 10.1021/tx900417f 1:CAS:528:DC%2BC3cXhvFWgtLc%3D
24. AK Ghose VN Viswanadhan JJ Wendoloski 1998 Prediction of hydrophobic (lipophilic) properties of small organic molecules using fragmental methods: an analysis of ALOGP and CLOGP methods J Phys Chem 102 3762 72 1:CAS:528: DyaK1cXis12rsrY%3D (Pubitemid 128611348)
25. SR Langdon J Mulgrew GV Paolini WP van Hoorn 2010 Predicting cytotoxicity from heterogeneous data sources with Bayesian learning J Chem Inf 2 11 1:CAS:528:DC%2BC3cXhs1Sht7%2FK
26. M Hann B Hudson X Lewell R Lifely L Miller N Ramsden 1999 Strategic pooling of compounds for high-throughput screening J Chem Inf Comput Sci 39 897 902 10529988 1:CAS:528:DyaK1MXksVWkt78%3D
27. JF Blake 2005 Identification and evaluation of molecular properties related to preclinical optimization and clinical fate Med Chem (Shariqah (United Arab Emirates)) 1 649 55 1:CAS:528:DC%2BD2MXhtFyht7vO
28. CK Stover P Warrener DR VanDevanter DR Sherman TM Arain MH Langhorne, et al. 2000 A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis Nature 405 962 6 10879539 10.1038/35016103 1:CAS:528: DC%2BD3cXks1Wksb0%3D (Pubitemid 30435054)
29. M Matsumoto H Hashizume T Tomishige M Kawasaki H Tsubouchi H Sasaki, et al. 2006 OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice PLoS Med 3 e466 17132069 10.1371/journal.pmed.0030466 (Pubitemid 44875946)
30. WP Walters Ajay MA Murcko 1999 Recognizing molecules with drug-like properties Curr Opin Chem Biol 3 384 7 10419858 10.1016/S1367-5931(99)80058-1 1:CAS:528:DyaK1MXlt1ejtb0%3D (Pubitemid 29376099)
31. B Gopalakrishnan V Aparna J Jeevan M Ravi GR Desiraju 2005 A virtual screening approach for thymidine monophosphate kinase inhibitors as antitubercular agents based on docking and pharmacophore models J Chem Inf Model 45 1101 8 16045305 10.1021/ci050064z 1:CAS:528:DC%2BD2MXksVOrtrs%3D (Pubitemid 41156710)
32. JA Maddry S Ananthan RC Goldman JV Hobrath CD Kwong C Maddox, et al. 2009 Antituberculosis activity of the molecular libraries screening center network library Tuberculosis (Edinburgh, Scotland) 89 354 63 10.1016/j.tube.2009.07.006 1:CAS:528:DC%2BC3cXhtlaktbY%3D